Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective follow-up study of children aged 23–25 months born to mothers treated with hydroxyprogesterone caproate for prevention of preterm birth
2011-000105-53Phase 3Active
- Sponsor
- Hologic, Inc.
- Start
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in preterm birth comparing Maternal 17P exposure with Maternal vehicle exposure (2 arms). Primary endpoint: Proportion of children below developmental cut-off. Started Feb 2011; status: active.
02
Drugs
hydroxyprogesterone caproate
03
Conditions
preterm birth
Beyond the preview
Go deeper on 2011-000105-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000105-53.